Inx-08189, A Phosphoramidate Prodrug of 6-O-methyl-2 '-C-methyl Guanosine, is A Potent Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic and Pharmacodynamic Properties

John H. Vernachio,Blair Bleiman,K. Dawn Bryant,Stanley Chamberlain,Damound Hunley,Jeff Hutchins,Brenda Ames,Elena Gorovits,Babita Ganguly,Andrea Hall,Alexander Kolykhalov,Yule Liu,Jerry Muhammad,Nicholas Raja,C. Robin Walters,Jin Wang,Karen Williams,Joseph M. Patti,Geoffrey Henson,Karolina Madela,Mohamed Aljarah,Arnaud Gilles,Christopher McGuigan

DOI: https://doi.org/10.1128/aac.01335-10

IF: 5.938

2011-01-01

Antimicrobial Agents and Chemotherapy

Abstract:ABSTRACT INX-08189 is an aryl-phosphoramidate of 6- O -methyl-2′- C -methyl guanosine. INX-08189 was highly potent in replicon assays, with a 50% effective concentration of 10 ± 6 nM against hepatitis C genotype 1b at 72 h. The inhibitory effect on viral replication was rapid, with a 50% effective concentration (EC 50 ) of 35 ± 8 nM at 24 h. An intracellular 2′- C -methyl guanosine triphosphate (2′- C -MeGTP) concentration of 2.43 ± 0.42 pmol/10 6 cells was sufficient to achieve 90% inhibition of viral replication. In vitro resistance studies confirmed that the S282T mutation in the NS5b gene conferred an approximately 10-fold reduction in sensitivity to INX-08189. However, the complete inhibition of S282T mutant replicons still could be achieved with an EC 90 of 344 ± 170 nM. Drug combination studies of INX-08189 and ribavirin indicated significant synergy in antiviral potency both in wild-type and S282T-expressing replicons. Genotype 1b replicons could be cleared after 14 days of culture when exposed to as little as 20 nM INX-08189. No evidence of mitochondrial toxicity was observed after 14 days of INX-08189 exposure in both HepG2 and CEM human cell lines. In vivo studies of rats and cynomolgus monkeys demonstrated that 2′- C -MeGTP concentrations in liver equivalent to the EC 90 could be attained after a single oral dose of INX-08189. Rat liver 2′- C -MeGTP concentrations were proportional to dose, sustained for greater than 24 h, and correlated with plasma concentrations of the nucleoside metabolite 2′- C -methyl guanosine. The characteristics displayed by INX-08189 support its continued development as a clinical candidate for the treatment of chronic HCV infection.